Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer.
- Published Article
- Publication Date
Mar 01, 2005
Bevacizumab has activity in epithelial ovarian carcinoma and larger scale trials are indicated.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/03/2016 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/15721449